1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
|
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<meta name="author" content="韩暮秋">
<meta name="subtitle" content="暮秋小屋">
<meta name="description" content="这里是暮秋小屋,思念和灵感的寄存处">
<meta name="keywords" content="韩暮秋,MuqiuHan,'Muqiu Han', 'muqiu han', muqiuhan">
<title>
胆红素与冠心病:抗氧化保护的证据与争议 |
暮秋小屋
</title>
<link rel="icon" href="/favicon.ico">
<!-- stylesheets list from _config.yml -->
<link rel="stylesheet" href="/css/style.css">
<link rel="preload" href="/fonts/TensentypeCode.woff2" as="font" type="font/woff2" crossorigin>
<!-- scripts list from _config.yml -->
<script
src="/js/menu.js"></script>
<script
src="https://polyfill.alicdn.com/polyfill.js?features=es6"></script>
<script
id="MathJax-script"
async
src="https://lf6-cdn-tos.bytecdntp.com/cdn/expire-1-M/mathjax/3.2.0/es5/tex-mml-chtml.js"></script>
<meta name="generator" content="Hexo 6.3.0"><style>mjx-container[jax="SVG"] {
direction: ltr;
}
mjx-container[jax="SVG"] > svg {
overflow: visible;
}
mjx-container[jax="SVG"][display="true"] {
display: block;
text-align: center;
margin: 1em 0;
}
mjx-container[jax="SVG"][justify="left"] {
text-align: left;
}
mjx-container[jax="SVG"][justify="right"] {
text-align: right;
}
g[data-mml-node="merror"] > g {
fill: red;
stroke: red;
}
g[data-mml-node="merror"] > rect[data-background] {
fill: yellow;
stroke: none;
}
g[data-mml-node="mtable"] > line[data-line] {
stroke-width: 70px;
fill: none;
}
g[data-mml-node="mtable"] > rect[data-frame] {
stroke-width: 70px;
fill: none;
}
g[data-mml-node="mtable"] > .mjx-dashed {
stroke-dasharray: 140;
}
g[data-mml-node="mtable"] > .mjx-dotted {
stroke-linecap: round;
stroke-dasharray: 0,140;
}
g[data-mml-node="mtable"] > svg {
overflow: visible;
}
[jax="SVG"] mjx-tool {
display: inline-block;
position: relative;
width: 0;
height: 0;
}
[jax="SVG"] mjx-tool > mjx-tip {
position: absolute;
top: 0;
left: 0;
}
mjx-tool > mjx-tip {
display: inline-block;
padding: .2em;
border: 1px solid #888;
font-size: 70%;
background-color: #F8F8F8;
color: black;
box-shadow: 2px 2px 5px #AAAAAA;
}
g[data-mml-node="maction"][data-toggle] {
cursor: pointer;
}
mjx-status {
display: block;
position: fixed;
left: 1em;
bottom: 1em;
min-width: 25%;
padding: .2em .4em;
border: 1px solid #888;
font-size: 90%;
background-color: #F8F8F8;
color: black;
}
foreignObject[data-mjx-xml] {
font-family: initial;
line-height: normal;
overflow: visible;
}
.MathJax path {
stroke-width: 3;
}
mjx-container[display="true"] {
overflow: auto hidden;
}
mjx-container[display="true"] + br {
display: none;
}
</style></head>
<body>
<div class="wrapper">
<div class="header">
<div class="flex-container">
<div class="header-inner">
<div class="site-brand-container">
<a href="/">
暮秋小屋
</a>
</div>
<div id="menu-btn" class="menu-btn" onclick="toggleMenu()">
菜单
</div>
<nav class="site-nav">
<ul class="menu-list">
<li class="menu-item">
<a href="/">
主页
</a>
</li>
<li class="menu-item">
<a href="/categories/gallery/">
日记本
</a>
</li>
<li class="menu-item">
<a href="/tags/Medicine/">
泛医学
</a>
</li>
<li class="menu-item">
<a href="/tags/Technique/">
计算机
</a>
</li>
<li class="menu-item">
<a href="/tags/Life/">
生活
</a>
</li>
<li class="menu-item">
<a href="/archives">
全部
</a>
</li>
<li class="menu-item">
<a href="/about">
关于
</a>
</li>
<li class="menu-item">
<a href="/search">搜索</a>
</li>
</ul>
</nav>
</div>
</div>
</div>
<div class="main">
<div class="flex-container">
<article id="post">
<div class="post-head">
<div class="post-info">
<div class="tag-list">
<span class="post-tag">
<a href="/tags/Medicine/">
Medicine
</a>
</span>
</div>
<div class="post-title">
胆红素与冠心病:抗氧化保护的证据与争议
</div>
<span class="post-date">
Aug 15, 2026
</span>
</div>
<div class="post-img">
<div class="h-line-primary"></div>
</div>
</div>
<div class="post-content">
<p>体检报告上"间接胆红素轻度升高"是一个很常见的发现。多数时候医生会说"没事,可能是吉尔伯特综合征",但网上流传着另一种说法:胆红素高的人心脏更好,因为胆红素是强效抗氧化剂。这个说法从 1987 年一篇《Science》论文开始,经历了从机制、临床观察到大型遗传学研究的完整验证,最后得到的结论比想象中复杂得多——它部分成立,但"升高胆红素能保护心脏"这个因果命题,在目前最强的证据里并不成立。</p>
<h2 id="起点-1987-年-胆红素被重新定义"><a class="header-anchor" href="#起点-1987-年-胆红素被重新定义">¶</a>起点:1987 年,胆红素被重新定义</h2>
<p>在 1987 年之前,胆红素在医学教科书里的身份是血红素分解的"有毒废料"——新生儿黄疸、肝病黄疸的主角。加州大学伯克利分校的 Stocker 和 Ames 团队首次证明:未结合(间接)胆红素其实是一种极其强效的脂溶性抗氧化剂<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup>。</p>
<ul>
<li>在生理组织氧浓度(2% 氧)下,胆红素抑制脂质过氧化的效率<strong>超过 α-生育酚(维生素 E)</strong>——后者当时被认为是脂质过氧化最强的内源性抗氧化剂;</li>
<li>1 分子白蛋白结合型胆红素可清除约 2 分子过氧自由基,血液中正常存在的少量胆红素足以保护白蛋白结合脂肪酸不被氧化<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>;</li>
<li>反应机理是氢原子转移(HAT):供氢基团是四吡咯结构两端二吡咯酮环的 N-H 键,动力学实测 1 分子胆红素可清除约 2 分子过氧自由基<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup>。</li>
</ul>
<p>此后四十年的生化研究不断补充机制:胆红素与 α-生育酚构成协同抗氧化网络(添加胆红素可使维生素 E 的消耗停止)<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup>;生理浓度胆红素可清除氯胺并抑制髓过氧化物酶(MPO)诱导的蛋白和脂质氧化<sup class="footnote-ref"><a href="#fn5" id="fnref5">[5]</a></sup>;2020 年后又发现胆红素是 PPAR-α 的选择性内源性配体,能重塑白色脂肪组织代谢,因此被称为"黄色激素"(the yellow hormone)<sup class="footnote-ref"><a href="#fn6" id="fnref6">[6]</a></sup><sup class="footnote-ref"><a href="#fn7" id="fnref7">[7]</a></sup>。</p>
<p>但抗氧化并非无限度:细胞实验显示,细胞内未结合胆红素蓄积超过约 25 ng/mg 蛋白后,从抗氧化转为<strong>促氧化并产生细胞毒性</strong><sup class="footnote-ref"><a href="#fn8" id="fnref8">[8]</a></sup>——这为"为什么只有轻度升高有益"提供了分子解释。</p>
<h2 id="临床观察-低胆红素与冠心病风险"><a class="header-anchor" href="#临床观察-低胆红素与冠心病风险">¶</a>临床观察:低胆红素与冠心病风险</h2>
<p>机制研究之后,临床流行病学接棒。1994 年 Schwertner 等在血管造影确诊的冠心病男性队列中首次发现:ln(总胆红素)与冠脉疾病严重程度独立负相关,总胆红素下降 50%,处于更严重冠脉疾病分级的几率增加 47%,关联强度"与收缩压相当"<sup class="footnote-ref"><a href="#fn9" id="fnref9">[9]</a></sup>。</p>
<p>2002 年,查尔斯大学 Vítek 团队做了一个更直接的人群对照:50 例 40 岁以上的吉尔伯特综合征患者 vs 2296 例一般人群,吉尔伯特组缺血性心脏病患病率仅 <strong>2%</strong>,对照组 <strong>12.1%</strong>(P<0.05),且吉尔伯特组血清总抗氧化能力显著更高<sup class="footnote-ref"><a href="#fn10" id="fnref10">[10]</a></sup>。</p>
<p>2006 年弗雷明汉心脏研究把证据推到基因层面:按 UGT1A1*28 基因型(吉尔伯特综合征的遗传基础,人群频率约 11%)分层,7/7 纯合子携带者心血管疾病风险 HR = 0.36(95% CI 0.18–0.74),冠心病 HR = 0.30<sup class="footnote-ref"><a href="#fn11" id="fnref11">[11]</a></sup>。这组数据至今仍被广泛引用。</p>
<p>后续荟萃分析确认了方向:每升高 1 个标准差胆红素,心血管风险约降 7%–10%<sup class="footnote-ref"><a href="#fn12" id="fnref12">[12]</a></sup>;生理范围内胆红素升高使首次心梗长期风险降 22%(RR 0.78)<sup class="footnote-ref"><a href="#fn13" id="fnref13">[13]</a></sup>;卒中风险最高 vs 最低组 RR = 0.85<sup class="footnote-ref"><a href="#fn14" id="fnref14">[14]</a></sup>。他汀人群 13 万人数据显示 L 形关联:与 10 μmol/L 相比,5 μmol/L 者心血管事件 +18%、心梗 +34%<sup class="footnote-ref"><a href="#fn15" id="fnref15">[15]</a></sup>。</p>
<p>不过观察性证据有两个长期被忽视的软肋:一是<strong>吸烟混杂</strong>——吸烟者 42% 处于胆红素最低四分位,戒烟后胆红素回升,"低胆红素 + 高心血管风险"有一部分是吸烟驱动的<sup class="footnote-ref"><a href="#fn16" id="fnref16">[16]</a></sup>;二是<strong>性别差异</strong>——阳性证据大多来自男性,女性中关联弱或不显著<sup class="footnote-ref"><a href="#fn17" id="fnref17">[17]</a></sup><sup class="footnote-ref"><a href="#fn18" id="fnref18">[18]</a></sup>。</p>
<h2 id="分水岭-孟德尔随机化给出否定答案"><a class="header-anchor" href="#分水岭-孟德尔随机化给出否定答案">¶</a>分水岭:孟德尔随机化给出否定答案</h2>
<p>观察性关联无法区分因果与混杂。孟德尔随机化(MR)利用"基因型在受精时随机分配"这一自然实验,绕开吸烟、饮酒、生活方式等混杂,是检验因果性的最强观察设计。这个领域在 2013 年和 2023 年迎来了两次大型否定:</p>
<p><strong>哥本哈根三队列 MR(2013)</strong>:43,708 人测胆红素,67,068 人基因分型,含 11,686 例缺血性心脏病事件。观察性分析中胆红素最高三分位 HR = 0.86,但多因素校正后衰减为 0.93(不显著);而基因型分析(TT vs GG,胆红素升高约 95%)对缺血性心脏病的 OR = 1.03,完全无效。加上既往 8 项研究的荟萃:OR = 1.01(0.88–1.16)。结论原文:<strong>“血浆胆红素与缺血性心脏病风险无因果关联”</strong><sup class="footnote-ref"><a href="#fn19" id="fnref19">[19]</a></sup>。</p>
<p><strong>UK Biobank + FinnGen(2023)</strong>:46.3 万人基因分型 + 42.9 万人复现。观察性层面,高胆红素与总体健康、心梗、胆固醇等广泛结局强负相关;但遗传学层面,这些负相关在吉尔伯特基因型人群中<strong>全部未复现</strong>——基因预测的胆红素仅与胆道/肝脏病理显著相关(胆结石 OR = 1.16,P = 5.7×10⁻¹⁶)。结论原文:<strong>“遗传学分析提示胆红素对心血管疾病、慢阻肺及其他关键结局无因果保护作用”</strong><sup class="footnote-ref"><a href="#fn20" id="fnref20">[20]</a></sup>。</p>
<p>这两项研究分别代表欧洲最大样本和全球最大样本,事件数都足以检出真实效应。阴性结果的解释力很强:如果"胆红素保护心脏"的因果效应真实存在,这些设计理应能够发现。</p>
<h2 id="但事情没有完全结束"><a class="header-anchor" href="#但事情没有完全结束">¶</a>但事情没有完全结束</h2>
<p>欧洲的否定不等于全部。亚洲和非洲人群的部分 MR 研究给出了阳性信号:</p>
<ul>
<li><strong>韩/日人群多变量 MR(2024)</strong>:间接胆红素对缺血性卒中 OR = 0.76,但共定位分析未找到共享因果变异,阳性需谨慎<sup class="footnote-ref"><a href="#fn21" id="fnref21">[21]</a></sup>;</li>
<li><strong>非裔人群 MR(2021)</strong>:胆红素对高血压呈因果保护(β = −0.76)<sup class="footnote-ref"><a href="#fn22" id="fnref22">[22]</a></sup>;</li>
<li><strong>中国汉族</strong>:上海 2380 例冠脉造影人群,UGT1A1 rs887829 隐性模型与男性冠心病显著负相关(OR = 0.24)<sup class="footnote-ref"><a href="#fn23" id="fnref23">[23]</a></sup>;东风-同济队列 2 型糖尿病患者中,间接胆红素 Q4 vs Q1 的冠心病 HR = 0.74<sup class="footnote-ref"><a href="#fn24" id="fnref24">[24]</a></sup>。</li>
</ul>
<p>另外 2023 年《Circulation Research》的动物-人联合研究显示,胆红素缺乏小鼠的动脉粥样硬化斑块更不稳定(纤维帽变薄、斑块内出血),人冠脉斑块中血红素代谢上调——机制层面的保护证据仍在积累<sup class="footnote-ref"><a href="#fn25" id="fnref25">[25]</a></sup>。</p>
<p>而<strong>胆结石</strong>是唯一在基因型与结局层面完全一致的因果证据:61,212 人前瞻队列 + MR,胆红素最高十分位症状性胆结石 HR = 1.57,TT 纯合基因型 HR = 1.22,存在剂量-反应<sup class="footnote-ref"><a href="#fn26" id="fnref26">[26]</a></sup>。</p>
<h2 id="几个反直觉的细节"><a class="header-anchor" href="#几个反直觉的细节">¶</a>几个反直觉的细节</h2>
<ul>
<li><strong>剂量-反应是 U 形,不是越多越好</strong>:12 项前瞻研究荟萃显示风险最低点约在 17–20 μmol/L,过低过高都不利<sup class="footnote-ref"><a href="#fn27" id="fnref27">[27]</a></sup>;</li>
<li><strong>急性期方向反转</strong>:心梗或卒中急性期,高胆红素反而预示更差预后——急性期胆红素升高反映氧化应激负荷,是"损伤标记"而非保护因子。保护作用是长期慢性暴露的属性<sup class="footnote-ref"><a href="#fn13" id="fnref13:1">[13:1]</a></sup><sup class="footnote-ref"><a href="#fn28" id="fnref28">[28]</a></sup>;</li>
<li><strong>组分之争</strong>:不同研究中间接(未结合)与直接(结合)胆红素方向可能相反<sup class="footnote-ref"><a href="#fn29" id="fnref29">[29]</a></sup>;</li>
<li><strong>预测价值有限</strong>:加入胆红素后风险模型的 C 指数仅提升 0.0013(P=0.13),没有临床意义的预测增益<sup class="footnote-ref"><a href="#fn12" id="fnref12:1">[12:1]</a></sup>。</li>
</ul>
<h2 id="结论-一个准确的说法"><a class="header-anchor" href="#结论-一个准确的说法">¶</a>结论:一个准确的说法</h2>
<p>把四十年的证据放在一起,最准确的表述是:</p>
<blockquote>
<p><strong>生理性轻度高胆红素血症(吉尔伯特综合征)是心血管风险的独立反向生物标志物,具有真实而复杂的抗氧化、抗炎与代谢活性;但"胆红素因果性地保护心脏"在欧洲人群最强设计中未获支持,不能作为临床干预的依据。</strong></p>
</blockquote>
<p>对个体而言,体检发现孤立性间接胆红素轻度升高(排除溶血与肝病后)应视为良性状态——既不必因此放松标准的心血管风险管理(血压、血脂、吸烟、运动),也不应被当作"心脏有保护"的免死金牌。对用药而言,吉尔伯特综合征患者使用 UGT1A1 底物药物(如伊立替康)需关注暴露增加。</p>
<p>一个常被误读的细节值得记住:2006 年弗雷明汉那篇著名的 HR = 0.36 是<strong>基因型-结局关联研究</strong>,不是孟德尔随机化;真正的 MR 检验直到 2013 年才由哥本哈根团队完成,而它给出的是否定答案。这个领域的发展轨迹——从乐观叙事到大型否定、再到人群异质性的复杂图景——本身就是流行病学方法学进步的一个标本。</p>
<hr>
<h2 id="参考文献"><a class="header-anchor" href="#参考文献">¶</a>参考文献</h2>
<p><img src="/img/%E5%8C%BB%E5%AD%A6/%E8%83%86%E7%BA%A2%E7%B4%A0%E8%AF%81%E6%8D%AE%E6%A3%AE%E6%9E%97%E5%9B%BE.png" alt="胆红素水平与心血管结局:观察性 vs 遗传学证据的关键效应量"></p>
<hr class="footnotes-sep">
<section class="footnotes">
<ol class="footnotes-list">
<li id="fn1" class="footnote-item"><p>Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. <em>Bilirubin is an antioxidant of possible physiological importance.</em> Science. 1987;235(4792):1043-6. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/3029864/">PMID: 3029864</a> <a href="#fnref1" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn2" class="footnote-item"><p>Stocker R, Glazer AN, Ames BN. <em>Antioxidant activity of albumin-bound bilirubin.</em> Proc Natl Acad Sci USA. 1987;84(16):5918-22. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/3475708/">PMID: 3475708</a> <a href="#fnref2" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn3" class="footnote-item"><p>Stocker R, et al. <em>Polypyrroles as antioxidants: kinetic studies on reactions of bilirubin and biliverdin dimethyl esters with peroxyl radicals.</em> J Org Chem. 2006;71(1):180-9. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/16388613/">PMID: 16388613</a> <a href="#fnref3" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn4" class="footnote-item"><p>Neuzil J, Stocker R. <em>Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol…</em> J Biol Chem. 1994;269(24):16712-9. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/8206992/">PMID: 8206992</a> <a href="#fnref4" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn5" class="footnote-item"><p>Boon AC, et al. <em>Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation…</em> Free Radic Biol Med. 2015;86:259-68. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/26057938/">PMID: 26057938</a> <a href="#fnref5" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn6" class="footnote-item"><p>Gordon DM, et al. <em>Bilirubin remodels murine white adipose tissue…</em> J Biol Chem. 2020;295(30):10296-10310. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/32404366/">PMID: 32404366</a> <a href="#fnref6" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn7" class="footnote-item"><p>Vítek L, Tiribelli C. <em>Bilirubin: the yellow hormone?</em> J Hepatol. 2021;75(6):1485-1490. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/34153399/">PMID: 34153399</a> <a href="#fnref7" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn8" class="footnote-item"><p>Bianco A, et al. <em>The extent of intracellular accumulation of bilirubin determines its anti- or pro-oxidant effect.</em> Int J Mol Sci. 2020;21(21):8101. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/33143041/">PMID: 33143041</a> <a href="#fnref8" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn9" class="footnote-item"><p>Schwertner HA, Jackson WG, Tolan G. <em>Association of low serum concentration of bilirubin with increased risk of coronary artery disease.</em> Clin Chem. 1994;40(1):18-23. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/8287538/">PMID: 8287538</a> <a href="#fnref9" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn10" class="footnote-item"><p>Vítek L, Jirsa M, Brodanová M, et al. <em>Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels.</em> Atherosclerosis. 2002;160(2):449-56. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/11849670/">PMID: 11849670</a> <a href="#fnref10" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn11" class="footnote-item"><p>Lin JP, O’Donnell CJ, Schwaiger JP, et al. <em>Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study.</em> Circulation. 2006;114(14):1476-81. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/17000907/">PMID: 17000907</a> <a href="#fnref11" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn12" class="footnote-item"><p>Kunutsor SK, et al. <em>Circulating total bilirubin and risk of incident cardiovascular disease in the general population.</em> Arterioscler Thromb Vasc Biol. 2015;35(3):716-24. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/25593130/">PMID: 25593130</a> <a href="#fnref12" class="footnote-backref">↩︎</a> <a href="#fnref12:1" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn13" class="footnote-item"><p>Yao ME, et al. <em>Physiologically increased total bilirubin is associated with reduced risk of first myocardial infarction…</em> Nutr Metab Cardiovasc Dis. 2021;31(4):1076-1085. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/33612380/">PMID: 33612380</a> <a href="#fnref13" class="footnote-backref">↩︎</a> <a href="#fnref13:1" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn14" class="footnote-item"><p>Wang G, et al. <em>Association between bilirubin levels and risk of stroke: a systematic review and meta-analysis.</em> BMJ Open. 2023;13(5):e067833. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37164466/">PMID: 37164466</a> <a href="#fnref14" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn15" class="footnote-item"><p>Horsfall LJ, Nazareth I, Petersen I. <em>Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort.</em> Circulation. 2012;126(22):2556-64. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/23110860/">PMID: 23110860</a> <a href="#fnref15" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn16" class="footnote-item"><p>Schwertner HA. <em>Association of smoking and low serum bilirubin antioxidant concentrations.</em> Atherosclerosis. 1998;136(2):383-7. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/9543110/">PMID: 9543110</a> <a href="#fnref16" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn17" class="footnote-item"><p>Hopkins PN, et al. <em>Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease.</em> Arterioscler Thromb Vasc Biol. 1996;16(2):250-5. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/8620339/">PMID: 8620339</a> <a href="#fnref17" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn18" class="footnote-item"><p>Hunt SC, et al. <em>Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait…</em> Atherosclerosis. 2001;154(3):747-54. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/11257278/">PMID: 11257278</a> <a href="#fnref18" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn19" class="footnote-item"><p>Stender S, et al. <em>Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis.</em> J Intern Med. 2013;273(1):59-68. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22805420/">PMID: 22805420</a> <a href="#fnref19" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn20" class="footnote-item"><p>Hamilton FW, et al. <em>Effect of bilirubin and Gilbert syndrome on health: cohort analysis of observational, genetic, and Mendelian randomisation associations.</em> BMJ Med. 2023;2(1):e000467. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37456363/">PMID: 37456363</a> <a href="#fnref20" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn21" class="footnote-item"><p>Shin JW, et al. <em>Causal association between serum bilirubin and ischemic stroke: multivariable Mendelian randomization.</em> Epidemiol Health. 2024;46:e2024070. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/39210787/">PMID: 39210787</a> <a href="#fnref21" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn22" class="footnote-item"><p>Chen G, et al. <em>A UGT1A1 variant is associated with serum total bilirubin levels, which are causal for hypertension in African-ancestry individuals.</em> NPJ Genom Med. 2021;6(1):44. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/34117260/">PMID: 34117260</a> <a href="#fnref22" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn23" class="footnote-item"><p>Lin R, et al. <em>Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population.</em> Pharmacogenet Genomics. 2009;19(4):310-8. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/19238116/">PMID: 19238116</a> <a href="#fnref23" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn24" class="footnote-item"><p>Wang J, et al. <em>Serum bilirubin concentrations and incident coronary heart disease risk among patients with type 2 diabetes: the Dongfeng-Tongji cohort.</em> Acta Diabetol. 2017;54(3):257-264. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/27933515/">PMID: 27933515</a> <a href="#fnref24" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn25" class="footnote-item"><p>Chen W, et al. <em>Destabilization of atherosclerotic plaque by bilirubin deficiency.</em> Circ Res. 2023;132(7):812-824. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/36876485/">PMID: 36876485</a> <a href="#fnref25" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn26" class="footnote-item"><p>Stender S, et al. <em>Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease.</em> JAMA Intern Med. 2013;173(13):1222-8. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/23753274/">PMID: 23753274</a> <a href="#fnref26" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn27" class="footnote-item"><p>Zuo L, et al. <em>Dose-response association between bilirubin and cardiovascular disease: a systematic review and meta-analysis.</em> Angiology. 2022;73(9):807-816. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/35015578/">PMID: 35015578</a> <a href="#fnref27" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn28" class="footnote-item"><p>Zhao K, et al. <em>Association between bilirubin levels with incidence and prognosis of stroke: A meta-analysis.</em> Front Neurosci. 2023;17:1122235. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/36866331/">PMID: 36866331</a> <a href="#fnref28" class="footnote-backref">↩︎</a></p>
</li>
<li id="fn29" class="footnote-item"><p>Tang C, et al. <em>The association between bilirubin and hypertension among a Chinese ageing cohort: a prospective follow-up study.</em> J Transl Med. 2022;20(1):108. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/35246141/">PMID: 35246141</a> <a href="#fnref29" class="footnote-backref">↩︎</a></p>
</li>
</ol>
</section>
</div>
<script>
window.onload = detectors();
</script>
<div class="post-footer">
<div class="h-line-primary"></div>
<nav class="post-nav">
<div class="prev-item">
<div class="icon arrow-left"></div>
<div class="post-link">
<a href="/2026/08/15/BMI%E5%B9%B4%E9%BE%84%E4%B8%8E%E8%A1%80%E8%84%82%E5%BC%82%E5%B8%B8/">Prev</a>
</div>
</div>
<div class="next-item">
<div class="icon arrow-right"></div>
<div class="post-link">
<a href="/2026/05/28/%E5%A6%82%E4%BD%95%E5%9C%A8-DDD-CQRS-%E4%B8%AD%E5%A4%84%E7%90%86%E8%B7%A8%E8%81%9A%E5%90%88%E7%9A%84%E4%BA%8B%E5%8A%A1/">Next</a>
</div>
</div>
</nav>
</div>
<div class="post-comment">
</div>
</article>
</div>
</div>
<div class="footer">
<div class="flex-container">
<div class="footer-text">
韩暮秋 |
希望路过的人可以添点柴火让这里暖和点
</div>
</div>
</div>
</div>
<script src="/js/mermaid-zoom.js"></script>
</body>
</html>
|